

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 55612

Manuscript Type: OPINION REVIEW

Recent advances in the management of gastrointestinal stromal tumor

Ahmed M. Recent advances in the management of GIST

Monjur Ahmed

Abstract

Gastrointestinal stromal tumor (GIST) is a rare but an important clinical entity seen in our clinical practice. It is the most common mesenchymal tumor of the gastrointestinal tract and most common malignancy of the small intestine.

Match Overview

1	Internet 114 words crawled on 15-May-2020 www.cancer.gov	2%
2	Crossref 81 words "Gastrointestinal Stromal Tumor", Springer Science and Business Media LLC, 2019	1%
3	Internet 60 words link.springer.com	1%
4	Internet 49 words crawled on 20-Jan-2020 fp.amegroups.cn	1%
5	Crossref 48 words Anastasios Machairas, Eva Karamitopoulou, Dimitrios T sapralis, Theodore Karatzas, Nickolas Machairas, Evan	1%
6	Internet 42 words crawled on 17-Nov-2019 banglajol.info	1%
7	Internet 28 words crawled on 14-Apr-2015 www.e-sciencecentral.org	<1%
8	Crossref 25 words J.H. Chan, A.Y. Teoh. "Gastrointestinal Stromal Tumors", Elsevier BV, 2019	<1%
9	Crossref 21 words "Textbook of Gastrointestinal Oncology", Springer Science and Business Media LLC, 2019	<1%
10	Crossref 14 words J. Spencer Liles, Ching-Wei D. Tzeng, Joshua J. Short, Peter Kulesza, Martin J. Heslin. "Retroperitoneal and Int...	<1%
11	Crossref 10 words Jian-Hong Zhong, Liang Ma, Le-Qun Li, Hai-Ming Ru, Yin-Nong Zhao. "Adjuvant imatinib for gastrointestinal stro...	<1%



国内版 国际版

Gastrointestinal Stromal Tumors in 2020



Sign in

Add the Give with Bing extension >

ALL IMAGES VIDEOS

16,400,000 Results Any time ▾

Global Gastrointestinal Stromal Tumors (GISTs) Treatment ...

<https://www.marketwatch.com/press-release/global...>

Apr 20, 2020 · The MarketWatch News Department was not involved in the creation of the content. Apr 20, 2020 (CDN Newswire via Comtex) – A new research report titled, Global **Gastrointestinal Stromal Tumors** ...


Cancer, Gastrointestinal Stromal (GIST)

<https://www.ncbi.nlm.nih.gov/pubmed/32119428>

Gastrointestinal stromal tumors (GISTs) are the most common **mesenchymal tumors** of the **gastrointestinal (GI)** tract, accounting for 80% of all **GI tumors**, and 0.1 to 3% of all **gastrointestinal malignancies**.^[1] Approximately 30% of GISTs are malignant.^[2]

Images of Gastrointestinal Stromal tumors in 2020

<bing.com/images>



Related searches

gastrointestinal stromal tumor **images**
gastrointestinal stromal tumor **pathology**
gastrointestinal stromal tumor **of the stomach**
gastrointestinal stromal tumor **survival rate**
gastrointestinal stromal tumor **symptoms**
gastrointestinal stromal tumor **uptodate**
icd 10 gastrointestinal stromal tumor
gastrointestinal stromal tumors **gists treatment**



ALL

IMAGES

VIDEOS

232,000 Results

Any time ▾

Recent advances in managing gastrointestinal stromal tumor

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600003>

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms that arise in the gastrointestinal tract. ... This article presents an evaluation of current GIST management, discusses important practice points that may impact upon questions of therapy for primary and metastatic GISTs, emphasizes the most recent advances in the ...

Cited by: 5

Author: Florence Duffaud, Florence Duffaud, Axel ...

Publish Year: 2017

Recent advances in the management of gastrointestinal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950054>

Recent advances. The ACOSOG Z9001 study enrolled 713 patients with a localized GIST of greater than 3 cm in diameter [1]. Preliminary data showed a major reduction in the risk of recurrence, from 17% to 2% at 1 year ($P = 0.0001$), with a hazard ratio of 0.35. In the updated report [2], the difference in RFS was significant for all tumor size subgroups (i.e., 3-6 cm, 6-10 cm, and ≥ 10 cm).

Cited by: 5

Author: Florence Duffaud, Sebastien Salas, Than...

Publish Year: 2010

Recent advances in the treatment of gastrointestinal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987653>

Novel insights into the biology of gastrointestinal stromal tumors (GISTs) have revolutionized the therapeutic options for management of both localized and advanced GISTs. It was not until 1998 that Hirota and colleagues identified gain-of-function mutations of the receptor tyrosine kinase (RTK) KIT in the majority of GISTs as the primary oncogenic driver of the disease [Hirota et al. 1998].

Cited by: 69

Author: César Serrano, Suzanne George

Publish Year: 2014

Recent advances in the management of gastrointestinal ...

<https://link.springer.com/article/10.1007/s11912-003-0068-9> ▾

Abstract. Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described.

Cited by: 13

Author: Margaret von Mehren

Publish Year: 2003



Recent advances in managing gastrointestinal stromal tumor

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600003>

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms that arise in the **gastrointestinal** tract. ... This article presents an evaluation of current **GIST management**, discusses important practice points that may impact upon questions of therapy for primary and metastatic GISTs, emphasizes the most **recent advances** in the ...

Cited by: 5

Author: Florence Duffaud, Florence Duffaud, Axel...

Publish Year: 2017

Recent advances in the management of gastrointestinal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950054>

Recent advances. The ACOSOG Z9001 study enrolled 713 patients with a localized GIST of greater than 3 cm in diameter [1]. Preliminary data showed a major reduction in the risk of **recurrence**, from 17% to 2% at 1 year ($P=0.0001$), with a hazard ratio of 0.35. In the updated **report** [2], the difference in **RFS** was significant for all **tumor size** subgroups (i.e., 3-6 cm, 6-10 cm, and ≥ 10 cm).

Cited by: 5

Author: Florence Duffaud, Sebastien Salas, Than...

Publish Year: 2010

Recent advances in the treatment of gastrointestinal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987653>

Novel insights into the biology of **gastrointestinal stromal tumors** (GISTs) have revolutionized the therapeutic options for **management** of both localized and **advanced GISTs**. It was not until 1998 that Hirota and colleagues identified gain-of-function mutations of the receptor tyrosine kinase (RTK) KIT in the majority of GISTs as the primary oncogenic driver of the disease [Hirota et al. 1998].

Cited by: 69

Author: César Serrano, Suzanne George

Publish Year: 2014

Recent advances in the management of gastrointestinal ...

<https://link.springer.com/article/10.1007/s11912-003-0068-9>

Gastrointestinal Stromal Tumors (Gists)

Medical condition

A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine.

[NIH](#)

Symptoms

The symptoms depend on the size of the tumor and where it's located. Because of this, symptoms often vary in severity and from one person to another.

Some of the more common symptoms include:

- bloody stools
- pain or discomfort in the abdomen
- nausea and...

[Read more on Healthline](#)

Causes

There are only a few known risk factors for GISTs:

Age

The most common age to develop a GIST is between 50 and 80. While GISTs can happen in people younger than 40, they are extremely rare.

Genes

The majority of GISTs happen randomly and have no...

[Read more on Healthline](#)

Treatments